Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (331-340 of 377) with videos related to

Pageof 38
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical RecurrenceJeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
European Urology Focus|September 10, 2019
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen DeprivationStephanie G C Kroeze, Christoph Henkenberens, Nina Sophie Schmidt-Hegemann, et al.
European Radiology|November 5, 2025
ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancerSungmin Woo, Luca Russo, Samuel J Withey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 3, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical TrialWolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 11, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy PlanningJeremie Calais, Johannes Czernin, Minsong Cao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [<sup>68</sup>Ga]PSMA-PET-guided metastasis-directed therapyMarco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens, et al.
EJNMMI Research|July 29, 2021
[<sup>18</sup>F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinomaFelix N Harder, Friederike Jungmann, Georgios A Kaissis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
Frontiers in Oncology|May 27, 2021
Combining <sup>68</sup>Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter StudySimon Kirste, Stephanie G C Kroeze, Christoph Henkenberens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?Andrei Gafita, Hui Wang, Andrew Robertson, et al.
Pageof 38

Showing results (331-340 of 377) with videos related to

Sort By:
Pageof 38
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2017
Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical RecurrenceJeremie Calais, Wolfgang P Fendler, Matthias Eiber, et al.
European Urology Focus|September 10, 2019
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen DeprivationStephanie G C Kroeze, Christoph Henkenberens, Nina Sophie Schmidt-Hegemann, et al.
European Radiology|November 5, 2025
ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancerSungmin Woo, Luca Russo, Samuel J Withey, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 3, 2020
Impact of <sup>68</sup>Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical TrialWolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 11, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy PlanningJeremie Calais, Johannes Czernin, Minsong Cao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [<sup>68</sup>Ga]PSMA-PET-guided metastasis-directed therapyMarco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens, et al.
EJNMMI Research|July 29, 2021
[<sup>18</sup>F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinomaFelix N Harder, Friederike Jungmann, Georgios A Kaissis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2019
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate CancerWolfgang P Fendler, Manuel Weber, Amir Iravani, et al.
Frontiers in Oncology|May 27, 2021
Combining <sup>68</sup>Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter StudySimon Kirste, Stephanie G C Kroeze, Christoph Henkenberens, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 29, 2021
Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality?Andrei Gafita, Hui Wang, Andrew Robertson, et al.
Pageof 38